T IHE role of heparin in the pathogenesis of hiuminan atheroselerosis still requires considerable clarification. The fact that heparin is capable of altering the blood lipid picture,1-4 and that atheroselerosis is asso-(iated with increased blood lipid levels,5-4 naturally directed investigation to heparin deficiency as a contributing factor. It has beeni reported that the blood heparinoids are reduced in atherosclerotic subjects8' 9 and also that heparin administered therapeutically exerts a favorable influence on persons with (oronary atheromna.1 0 11 Heparin, however, does not act directly on blood lipids, its action I)eing brought about by the elaboration of clearing factor,12 which is capable of clearing fat emulsions both in vivo and in vitro. It has beell shown that the elaboration of clearing factor is reduced in individuals with atheroselerosis,13 14 small doses of intravenous heparin producing less clearing following a fat meal in this group. The evidence that clearing factor is present in normal plasma1') 16 and can be extracted from normal tissues,17 increases in importance any possible disturbance of the clearing reaction manifested by the atheroselerotic individual. Disturbance of the physiology of fat trainsport resulting from a reduced clearing rate may therefore be a factor in the elevated lipid levels of the atheroselerotic individual. Further, in experimeiital nephrosis and diabetes," 8' 19 there is evidence of a reduced clearing factor response to heparin and both Recently it was found-'cl' 21 that niormial plasmia contained a substance, probably a glycoproteitn, capable of inhibiting clearing factor. The decreased clearing following small doses of heparin ini okler pl~el5so and atherosclerotic subj ects iii particular,13' 14 coul(l well be related to a higher level of iilhibitor in these groups. The possibility of au illcreased level of clearing factor inhibitor in illdividuals with atherosclerosis atid related conditions; was therefore considered worth inv-\estigatinig. Itideed rece nitly Klein and Lever22 reported that i(lioplatlie lhyperlipemiia was associated with inicreased clearing factor inhibitor activity--and Anigervall and Hood-2' 23 miade some iii conclusive observations on its presence in atherosclerotic suibjects.
In this paper the clearing factor inhibitor activity of the plasma of atherosclerotic, diabetic, and nephrotic subj ects is determined mll(l compared with that of younger stu(lelt controls and with controls of equivalent age. The source of lipemia-clearing factor used for the inhibitor studies was plasma taken from normal medical students after they were given heparin. On each day 1 or more students was given intravenously 1,000 units of heparin and 15 minutes later 10 ml. of blood were removed. It was placed in chilled oxalated tubes and the plasma was separated and kept at 4 C. until used later the same day. Since this procedure was repeated on each day, a different source of clearing factor was used on different days. In order to determine inhibitor activity 0.25 ml. of the active postheparin plasma was mixed with 0.25 ml. of the plasma to be tested and the resulting clearing activity was determined. The student controls were tested at the same time and under the same conditions as the other 3 groups, as far as possible a representative of all groups being incorporates in the series for each day. It was thus possible on each day or within each series (where 2 sources of clearing factor were used) to compare the amount of inhibition produced by the student control with that produced by the other patients. Thus the clearing factor inhibitor activity of the control, atherosclerotic, and diabetic groups could be compared with the student control.
METIIODS
Lipemia-clearing factor inhibitor activity. The clearing factor activity of the mixture of active post-heparin plasma with the plasma to be investigated was determined by the method of Grossman24 as modified by Day since it was found that the difference k, -kAt depended to some extent on the clearing factor activity of the serum used, as indicated by the k. value. This index was taken as a measure of clearing factor inhibitor activity in the test individual (relative to control). Table 1 gives the in vitro clearing rate (k) of post-heparin plasma when mixed with untreated plasma from students, age control, atheroselerotic, diabetic, and nephrotic subjects. On each day, (or in each series if more than one series was performed on the day) the same source of clearing factor was used and the student inhibitor activity was determined at the same time and under the same conditions as the other patients studied on that day. It was possible therefore to consider the student control as having zero inhibitor activity and to relate the inhibitor activity of the test subjects to their respective student control on this basis. In table 2 this has been done and the relative inhibitor activities (I) of the age control, atherosclerotic, and diabetic subjects have been calculated and compared.
RESULTS
It is apparent from tables 1 and 2 that there is greater clearing factor inhibitor activity in all 3 test groups than in the student group. In the age control series, 11 of the 14 subjects have more inhibitor activity than their respective student controls. In the remaining 3 the "negative inhibition " is simply an expression of greater inhibitor activity in the student than in that age control. The mean for -I, with its estimated standard error, is 15.3 + 5.7, an increased inhibitor activity with age that is statistically significant (p < 0.02).
In the atherosclerotic group 14 of the 17 patients demonstrated more inhibitor activity than the respective student controls. The mean value for I for this group was 14.0 + 6.3, this difference again being statistically significant (p < 0.05). When the atherosclerotic group was compared with the age control group, i.e., with normal individuals of similar age, no significant difference in inhibitor activity was detected. It would seem that the difference in inhibitor activity between the student and atherosclerotic groups may be explicable entirely on an age basis and not related to atherosclerosis as such.
In the diabetic group, when the younger diabetics (< 35 years) are excluded, the mean inhibitor activity (1) is 12.9 + 8.9. Because of the large variance this value is not significantly different from the student group, but it is of the same order as the other 2 "older groups." No significant difference in inhibitor activity exists between the diabetic and the age control or atherosclerotic individuals. Thus no specific increase in inhibitor activity can be attributed to the diabetic state. It is worth noting that in the 3 younger diabetics (26, 17 , and 30 years) the inhibitor activity is of the same order as the student controls. Thus when the age factor is eliminated, the increased inhibitor activity in this group is also eliminated.
Definite conclusions cannot be drawn about the 2 nephrotic subjects, but it is interesting that there is inhibitor activity (compared with the student control) in both. However this inhibition is similar in magnitude to that of the age controls investigated on the same day and can therefore be accounted for purely on an age basis. DISCUSSION It has been found that the plasma of older individuals inhibits lipemia-clearing factor to a greater degree than younger controls. This elevated inhibitor activity with aging is in accord with the recent findings of Nikkili and Niemi,26 who have shown heparin to produce less clearing factor in older subjects than in younger controls. The presence of more inhibitor activity as shown here would reduce the post-heparin clearing activity and thus account for this apparently reduced response. In a previous communications we have recorded the fact that protamine elevates the serum total fatty acids in normal students, but has no effect in older age groups. This was interpreted to indicate a deficiency in circulating heparin produced with aging. Hollett and Meng27 have shown that protamine is capable of inhibiting clearing factor and that its action on lipids may be related partly to this inhibition. The changing response with age of fatty acids to protamine could therefore also be explained in terms of an increased clearing factor inhibitor activity. With the small amount of normal clearing factor already inhibited in the older age groups, the inhibiting effect of protamine would not be able to manifest itself and minimal changes would result. The reduced fat tolerance with increasing age28' 29 can also be related to the increased inhibitor level.
Clearing factor, physiologically concerned with lipid removal following a fat meal, is prevented from adequately doing so by the increased inhibitor activity and the fat level is able to rise to a higher level in the older age groups. The findings of Block 
